Last reviewed · How we verify
injectable MS DMT
Injectable MS DMT refers to disease-modifying therapies for multiple sclerosis administered by injection that work through various immunomodulatory mechanisms to reduce inflammation and slow disease progression.
Injectable MS DMT refers to disease-modifying therapies for multiple sclerosis administered by injection that work through various immunomodulatory mechanisms to reduce inflammation and slow disease progression. Used for Relapsing-remitting multiple sclerosis, Clinically isolated syndrome with MRI features consistent with MS.
At a glance
| Generic name | injectable MS DMT |
|---|---|
| Sponsor | Biogen |
| Drug class | Immunomodulator (disease-modifying therapy) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Biogen's injectable MS DMTs include agents such as interferon beta and glatiramer acetate, which modulate immune responses to reduce inflammatory attacks on the central nervous system. These therapies decrease the frequency and severity of relapses and slow the accumulation of disability in relapsing-remitting multiple sclerosis. The exact mechanisms vary by specific agent but generally involve shifting immune responses away from pro-inflammatory Th1/Th17 cells toward anti-inflammatory Th2 responses.
Approved indications
- Relapsing-remitting multiple sclerosis
- Clinically isolated syndrome with MRI features consistent with MS
Common side effects
- Injection site reactions
- Flu-like symptoms
- Headache
- Fever
- Myalgia
- Depression
- Liver enzyme elevation
Key clinical trials
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- B-cell Depletion in Offspring to Women With MS Under Immunomodulatory Treatment
- Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
- Tecfidera and the Gut Microbiota (PHASE4)
- Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- injectable MS DMT CI brief — competitive landscape report
- injectable MS DMT updates RSS · CI watch RSS
- Biogen portfolio CI